» Articles » PMID: 30997508

Timeliness of Human Immunodeficiency Virus Diagnosis and Antiretroviral Treatment Initiation in the Era of Universal Testing and Treatment

Overview
Journal J Infect Dis
Date 2019 Apr 19
PMID 30997508
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We describe the timing of human immunodeficiency virus (HIV) diagnosis and antiretroviral treatment (ART) initiation after implementation of universal testing and treatment policies in New York City (NYC).

Methods: Using NYC population-based HIV registry data for persons with HIV diagnosed from 2012 through 2015 and followed up through June 2017, we examined trends in the proportion with diagnosis soon after HIV infection (ie, with CD4 cell count ≥500/μL or with acute HIV infection) and used Kaplan-Meier plots and proportional hazards regression to examine the timing of ART initiation after diagnosis.

Results: Among 9987 NYC residents with HIV diagnosed from 2012 to 2015, diagnosis was early in 35%, and 87% started ART by June 2017. The annual proportion of persons with early diagnosis did not increase appreciably (35% in 2012 vs 37% in 2015; P = .08). By 6 months after diagnosis, 62%, 67%, 72% and 77% of persons with HIV diagnosed in 2012, 2013, 2014, or 2015, respectively, had started ART, with median (interquartile range) times to ART initiation of 3.34 (1.34-12.75), 2.62 (1.28-10.13), 2.16 (1.15-7.11), and 2.03 (1.11-5.61) months, respectively.

Conclusions: Although recommendations for ART initiation on diagnosis are increasingly being implemented, the findings of the current study suggest that immediate treatment initiation is not universal. Continued efforts are needed to expand and better target HIV testing to promote earlier diagnosis.

Citing Articles

CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre....

Ruiz-Burga E, Tariq S, Touloumi G, Gill J, Nicholls E, Sabin C BMJ Open. 2023; 13(5):e070837.

PMID: 37169505 PMC: 10186449. DOI: 10.1136/bmjopen-2022-070837.


HIV Epidemiology, Care, and Treatment Outcomes Among Student and Nonstudent Youths Living With HIV in Southwest China Between 1996 and 2019: Historical Cohort Study.

Wang N, Lan G, Zhu Q, Chen H, Huang J, Meng Q JMIR Public Health Surveill. 2023; 9:e38881.

PMID: 36826980 PMC: 10007008. DOI: 10.2196/38881.


HIV and Drug-Resistant Subtypes.

Nastri B, Pagliano P, Zannella C, Folliero V, Masullo A, Rinaldi L Microorganisms. 2023; 11(1).

PMID: 36677513 PMC: 9861097. DOI: 10.3390/microorganisms11010221.


A province-wide HIV initiative to accelerate initiation of treatment-as-prevention and virologic suppression in British Columbia, Canada: a population-based cohort study.

Nanditha N, Dong X, Tafessu H, Wang L, Lu M, Barrios R CMAJ Open. 2022; 10(1):E27-E34.

PMID: 35042692 PMC: 8920539. DOI: 10.9778/cmajo.20210093.


Durable Viral Suppression Among People with HIV and Problem Substance Use in the Era of Universal Antiretroviral Treatment.

Paschen-Wolff M, Campbell A, Tross S, Choo T, Pavlicova M, Braunstein S AIDS Behav. 2021; 26(2):385-396.

PMID: 34331177 PMC: 8800950. DOI: 10.1007/s10461-021-03392-9.